acalabrutinib   Click here for help

GtoPdb Ligand ID: 8912

Synonyms: ACP-196 | Calquence® | Example 6 [US20140155385 A1] [2]
Approved drug PDB Ligand Immunopharmacology Ligand
acalabrutinib is an approved drug (FDA (2017), EMA (2020))
Compound class: Synthetic organic
Comment: Acalabrutinib is an orally available second-generation, selective and irreversible inhibitor of Bruton tyrosine kinase (BTK) [6], being investigated for its potential antineoplastic activity (in multiple haematologic malignancies and solid tumours), as well as a potential therapy for rheumatoid arthritis. Acalabrutinib covalently bonds to Cysteine-481 in BTK.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 118.51
Molecular weight 465.19
XLogP 4.09
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC#CC(=O)N1CCCC1c1nc(c2n1ccnc2N)c1ccc(cc1)C(=O)Nc1ccccn1
Isomeric SMILES CC#CC(=O)N1CCC[C@H]1c1nc(c2n1ccnc2N)c1ccc(cc1)C(=O)Nc1ccccn1
InChI InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1
InChI Key WDENQIQQYWYTPO-IBGZPJMESA-N
Bioactivity Comments
Acalabrutinib has improved selectivity, pharmacologic features (rapid oral absorption, favourable plasma exposure and a short half-life for example) and in vivo target coverage compared to the first generation BTK inhibitor, ibrutinib [3,6]. The IC50 values in the table below are for kinases that contain a cysteine residue aligning with Cysteine-481 in BTK (with exception of LYN). Unlike ibrutinib, acalabrutinib is devoid of activity across the SRC family kinases (IC50s > 1000 nM) [3].
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Bruton tyrosine kinase Primary target of this compound Hs Inhibitor Inhibition >8.0 pEC50 - 2
pEC50 >8.0 (EC50 <1x10-8 M) [2]
FYN proto-oncogene, Src family tyrosine kinase Hs Inhibitor Inhibition <6.0 pEC50 - 2
pEC50 <6.0 (EC50 >1x10-6 M) [2]
LCK proto-oncogene, Src family tyrosine kinase Hs Inhibitor Inhibition <6.0 pEC50 - 2
pEC50 <6.0 (EC50 >1x10-6 M) [2]
LYN proto-oncogene, Src family tyrosine kinase Hs Inhibitor Inhibition 6.0 pEC50 - 2
pEC50 6.0 (EC50 1x10-6 M) [2]
SRC proto-oncogene, non-receptor tyrosine kinase Hs Inhibitor Inhibition <6.0 pEC50 - 2
pEC50 <6.0 (EC50 >1x10-6 M) [2]
Bruton tyrosine kinase Primary target of this compound Hs Inhibitor Inhibition 8.3 pIC50 - 3
pIC50 8.3 (IC50 5.1x10-9 M) [3]
BMX non-receptor tyrosine kinase Hs Inhibitor Inhibition 7.3 pIC50 - 3
pIC50 7.3 (IC50 4.6x10-8 M) [3]
tec protein tyrosine kinase Hs Inhibitor Inhibition 7.0 pIC50 - 3
pIC50 7.0 (IC50 9.3x10-8 M) [3]
TXK tyrosine kinase Hs Inhibitor Inhibition 6.4 pIC50 - 3
pIC50 6.4 (IC50 3.68x10-7 M) [3]
BLK proto-oncogene, Src family tyrosine kinase Hs Inhibitor Inhibition <6.0 pIC50 - 3
pIC50 <6.0 (IC50 >1x10-6 M) [3]
IL2 inducible T cell kinase Hs Inhibitor Inhibition <6.0 pIC50 - 3
pIC50 <6.0 (IC50 >1x10-6 M) [3]
Janus kinase 3 Hs Inhibitor Inhibition <6.0 pIC50 - 3
pIC50 <6.0 (IC50 >1x10-6 M) [3]
LYN proto-oncogene, Src family tyrosine kinase Hs Inhibitor Inhibition <6.0 pIC50 - 3
pIC50 <6.0 (IC50 >1x10-6 M) [3]
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
erb-b2 receptor tyrosine kinase 4 Hs Inhibitor Inhibition 7.8 pIC50 - 3
pIC50 7.8 (IC50 1.6x10-8 M) [3]
epidermal growth factor receptor Hs Inhibitor Inhibition <6.0 pIC50 - 3
pIC50 <6.0 (IC50 >1x10-6 M) [3]
erb-b2 receptor tyrosine kinase 2 Hs Inhibitor Inhibition <6.0 pIC50 - 3
pIC50 <6.0 (IC50 >1x10-6 M) [3]